MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:43Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Anorectics]]
			[[Category:Sympathomimetics]]
			[[Category:Schedule IV controlled substances]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #168

2026-05-23T04:15:09Z

parser-claude batch MedTemplate pre-fill, Top 300 #168

New page

{{MedTemplate
| generic = Phentermine
| brand = Adipex-P, Lomaira (low-dose); with topiramate as Qsymia
| structure =
| classes = [[:Category:Anorectics|Anorectic (appetite suppressant)]], [[:Category:Sympathomimetics|Sympathomimetic]], [[:Category:Schedule_IV_controlled_substances|Schedule IV controlled substance]]
| uses = <vote slug="obesity-treatment-use">Short-term adjunct in obesity (BMI ≥30, or ≥27 with risk factors)</vote>
| starting_dose = 15-37.5 mg PO once daily before breakfast or 1-2 hours after; Lomaira 8 mg TID
| preparations = 15, 30, 37.5 mg capsules/tablets; 8 mg Lomaira
| fda_max = 37.5 mg/d
| pill_id =
| routes = Oral
| onset = Appetite suppression within hours; weight loss over weeks-months
| duration = ~12-14 hours
| halflife = ~25 hours<ref name="adipex-label">FDA Prescribing Information, Adipex-P (phentermine HCl), Teva, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/085128s072lbl.pdf</ref>
| bioavailability = High (oral)<ref name="adipex-label" />
| pregnancy = Contraindicated in pregnancy.{{citation needed}}
| legal = [[USLegal:Schedule IV|Schedule IV controlled substance]] in US; '''labeled for short-term use (≤12 weeks)''' due to limited long-term safety data and tachyphylaxis concerns. Combination with fenfluramine (the now-withdrawn "fen-phen" regimen) caused valvular heart disease in the 1990s — modern phentermine-only and phentermine-topiramate (Qsymia) use lack that complication
| mechanism = <vote slug="phentermine-mech-claim">Phentermine is a sympathomimetic amphetamine analog that increases norepinephrine release in the hypothalamus, producing appetite suppression through central α1 adrenergic activation; secondary dopaminergic effects contribute to the modest abuse-liability profile that places it in Schedule IV.</vote> Phentermine-topiramate (Qsymia) combination achieves greater weight loss than either alone via topiramate's appetite-suppressing and satiety-enhancing GABAergic effects. Caution in cardiovascular disease, hypertension, hyperthyroidism, and any prior valvulopathy<ref name="adipex-label" />.
}}

== References ==
<references />

Phentermine - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #168